AstraZeneca said on Friday a late-stage study confirmed its top-selling drug, Tagrisso, had considerably helped sufferers with a type of lung cancer live longer without the illness worsening.
The British drug manufacturer announced general positive survival outcomes from the study in sufferers with epidermal growth issue receptor-mutated metastatic non-small cell lung cancer.
Tagrisso was the one medicine that had shown a statistically-vital overall survival benefit in this type of illness setting, AstraZeneca said.
The corporate has shifted deeper into cancer remedy through wide-ranging offers, including those for immunotherapy and focused therapy. Earlier this year, it agreed on multi-billion-dollar oncology contract with Japan’s Daiichi Sankyo Co.
Sales from AstraZeneca’s oncology unit had surged 57% to $2.17 billion in Q2, accounting for 38% of total product sales, with income Tagrisso nearly folding to $784 million.
AstraZeneca had further raised its product sales estimate for 2019, due to robust sales of cancer medication.
“Today’s positive outcomes show that Tagrisso provides an unprecedented survival result versus earlier standard-of-care … reaffirming Tagrisso as the 1st-line standard-of-care,” José Baselga, executive VP, oncology R&D, stated in a statement.
Tagrisso is currently accredited in 74 nations, including the US, Japan, and the European Union, for treating the specific type of cancer.
AstraZeneca said Wednesday its cancer drug, Lynparza, was successful in helping sufferers with metastatic prostate cancer and specific genetic changes live longer without the illness worsening, compared with the standard of care.